Pancreatic and duodenal homeobox 1 (PDX1) mRNA (PDX1 mRNA)

Pancreatic and duodenal homeobox 1 (PDX1) mRNA encodes a homeodomain transcription factor essential for early pancreatic development and the differentiation of endocrine cells (UniProt P52945). In adults, the encoded protein maintains beta-cell function and regulates the expression of genes like insulin, GLUT2, and glucokinase (NCBI Gene 3651). Mutations or reduced expression of PDX1 are linked to pancreatic agenesis, maturity-onset diabetes of the young type 4 (MODY4), and beta-cell dysfunction in Type 2 diabetes (PubMed: 10510058). As a therapeutic target, PDX1 mRNA is used in regenerative medicine to induce cellular transdifferentiation, where synthetic modified mRNA is delivered to non-beta cells to convert them into functional insulin-secreting cells (PubMed: 24503114). This mRNA-based approach avoids the risks of permanent genomic integration associated with DNA-based gene therapy. Current research focuses on using lipid nanoparticles (LNPs) to deliver PDX1 mRNA efficiently to target tissues to provide a renewable source of endogenous insulin. Challenges associated with this target include the transient nature of mRNA expression and the requirement for precise delivery to avoid off-target cellular reprogramming.

Other names

Insulin promoter factor 1 mRNAIPF1 mRNASomatostatin-transactivating factor 1 mRNASTF-1 mRNAIslet-specific duodenal-homeobox 1 mRNAIDX-1 mRNAGlucose-sensitive factor mRNAGSF mRNA

mRNA replacement therapy or cellular reprogramming to induce the formation of insulin-secreting beta-like cells from non-beta cell precursors.